Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

BeiGene Ltd

Current price
181.16 USD -2.86 USD (-1.55%)
Last closed 187.49 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 20 428 349 440 USD
Yield for 12 month -4.00 %
21.11.2021 - 28.11.2021

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., Enlivex Therapeutics Ltd., Chime Biologics Limited, and Nanjing Leads Biolabs Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands. Address: 55 Cambridge Parkway, Cambridge, MA, United States, 02142


WallStreet Target Price

286.55 USD

P/E ratio

Dividend Yield

Current Year

+1 415 921 000 USD

Last Year

+1 176 283 000 USD

Current Quarter

+781 308 000 USD

Last Quarter

+595 261 000 USD

Current Year

-511 062 000 USD

Last Year

-447 862 000 USD

Current Quarter

+684 999 000 USD

Last Quarter

+76 507 000 USD

Key Figures BGNE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -1 214 903 040 USD
Operating Margin TTM -17.15 %
PE Ratio
Return On Assets TTM -13.2 %
PEG Ratio
Return On Equity TTM -22.8 %
Wall Street Target Price 286.55 USD
Revenue TTM 2 204 464 896 USD
Book Value 36.16 USD
Revenue Per Share TTM 21.13 USD
Dividend Share
Quarterly Revenue Growth YOY 101.6 %
Dividend Yield
Gross Profit TTM -511 062 000 USD
Earnings Share -9.22 USD
Diluted Eps TTM -9.22 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -43.53 %

Dividend Analytics BGNE

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BGNE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BGNE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 8.0835
Price Sales TTM 9.2668
Enterprise Value EBITDA -14.7186
Price Book MRQ 5.1871

Financials BGNE

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators BGNE

For 52 weeks

156.56 USD 280.62 USD
50 Day MA 181.97 USD
Shares Short Prior Month 1 201 907
200 Day MA 208.56 USD
Short Ratio 6.51
Shares Short 1 475 911
Short Percent 5.88 %